Poly(N-methyl-N-vinylacetamide) : A Strong Alternative to PEG for Lipid-Based Nanocarriers Delivering siRNA
© 2023 Wiley‐VCH GmbH..
Lipid-based nanocarriers have demonstrated high interest in delivering genetic material, exemplified by the success of Onpattro and COVID-19 vaccines. While PEGylation imparts stealth properties, it hampers cellular uptake and endosomal escape, and may trigger adverse reactions like accelerated blood clearance (ABC) and hypersensitivity reactions (HSR). This work highlights the great potential of amphiphilic poly(N-methyl-N-vinylacetamide) (PNMVA) derivatives as alternatives to lipid-PEG for siRNA delivery. PNMVA compounds with different degrees of polymerization and hydrophobic segments, are synthesized. Among them, DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine)-PNMVA efficiently integrates into lipoplexes and LNP membranes and prevents protein corona formation around these lipid carriers, exhibiting stealth properties comparable to DSPE-PEG. However, unlike DSPE-PEG, DSPE-PNMVA24 shows no adverse impact on lipoplexes cell uptake and endosomal escape. In in vivo study with mice, DSPE-PNMVA24 lipoplexes demonstrate no liver accumulation, indicating good stealth properties, extended circulation time after a second dose, reduced immunological reaction, and no systemic pro-inflammatory response. Safety of DSPE-PNMVA24 is confirmed at the cellular level and in animal models of zebrafish and mice. Overall, DSPE-PNMVA is an advantageous substitute to DSPE-PEG for siRNA delivery, offering comparable stealth and toxicity properties while improving efficacy of the lipid-based carriers by minimizing the dilemma effect and reducing immunological reactions, meaning no ABC or HSR effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Advanced healthcare materials - 13(2024), 8 vom: 31. März, Seite e2302712 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berger, Manon [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/adhm.202302712 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36485748X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36485748X | ||
| 003 | DE-627 | ||
| 005 | 20240329000203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/adhm.202302712 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM36485748X | ||
| 035 | |a (NLM)37994483 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berger, Manon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Poly(N-methyl-N-vinylacetamide) |b A Strong Alternative to PEG for Lipid-Based Nanocarriers Delivering siRNA |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley‐VCH GmbH. | ||
| 520 | |a Lipid-based nanocarriers have demonstrated high interest in delivering genetic material, exemplified by the success of Onpattro and COVID-19 vaccines. While PEGylation imparts stealth properties, it hampers cellular uptake and endosomal escape, and may trigger adverse reactions like accelerated blood clearance (ABC) and hypersensitivity reactions (HSR). This work highlights the great potential of amphiphilic poly(N-methyl-N-vinylacetamide) (PNMVA) derivatives as alternatives to lipid-PEG for siRNA delivery. PNMVA compounds with different degrees of polymerization and hydrophobic segments, are synthesized. Among them, DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine)-PNMVA efficiently integrates into lipoplexes and LNP membranes and prevents protein corona formation around these lipid carriers, exhibiting stealth properties comparable to DSPE-PEG. However, unlike DSPE-PEG, DSPE-PNMVA24 shows no adverse impact on lipoplexes cell uptake and endosomal escape. In in vivo study with mice, DSPE-PNMVA24 lipoplexes demonstrate no liver accumulation, indicating good stealth properties, extended circulation time after a second dose, reduced immunological reaction, and no systemic pro-inflammatory response. Safety of DSPE-PNMVA24 is confirmed at the cellular level and in animal models of zebrafish and mice. Overall, DSPE-PNMVA is an advantageous substitute to DSPE-PEG for siRNA delivery, offering comparable stealth and toxicity properties while improving efficacy of the lipid-based carriers by minimizing the dilemma effect and reducing immunological reactions, meaning no ABC or HSR effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PEG alternative | |
| 650 | 4 | |a lipid nanoparticles | |
| 650 | 4 | |a lipoplexes | |
| 650 | 4 | |a poly(N‐methyl‐N‐vinylacetamide) | |
| 650 | 4 | |a siRNA delivery | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a poly(N-methyl-N-vinylacetamide) |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a Phosphatidylethanolamines |2 NLM | |
| 650 | 7 | |a Polyvinyls |2 NLM | |
| 700 | 1 | |a Toussaint, François |e verfasserin |4 aut | |
| 700 | 1 | |a Ben Djemaa, Sanaa |e verfasserin |4 aut | |
| 700 | 1 | |a Maquoi, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Pendeville, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Evrard, Brigitte |e verfasserin |4 aut | |
| 700 | 1 | |a Jerôme, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Leblond Chain, Jeanne |e verfasserin |4 aut | |
| 700 | 1 | |a Lechanteur, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Mottet, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Debuigne, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Piel, Géraldine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced healthcare materials |d 2012 |g 13(2024), 8 vom: 31. März, Seite e2302712 |w (DE-627)NLM218710070 |x 2192-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:8 |g day:31 |g month:03 |g pages:e2302712 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/adhm.202302712 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 8 |b 31 |c 03 |h e2302712 | ||